Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic therapies via interference RNA, a powerful tool for rational drug design. Most advanced product of the company are treatments for glaucoma and dry eye syndrome. Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com)